Eli Lilly and Company Aktie News

Eli Lilly is a Strong Buy, driven by exceptional growth in obesity and diabetes drugs Mounjaro and Zepbound, plus pipeline innovation. LLY's diversified business mix, global reach, and proactive U.S. manufacturing investments position it well for regulatory and political developments. Despite sector headwinds and cautious market sentiment, LLY's robust earnings momentum and positive analyst rev...

Eli Lilly signed an agreement with Cipla , allowing the Indian drugmaker to sell its blockbuster weight-loss drug under a separate brand in the country, the companies said on Thursday.

Sold 6,430 shares of Eli Lilly and Company; estimated transaction value ~$4.78 million Post-trade holding: 61,292 shares valued at $46.77 million Position now 1% of fund AUM, which places it outside the fund's top five holdings

Eli Lilly is expected to present third-quarter results on Oct. 30 after the market opens. Wall Street analysts will be looking closely at sales growth for Mounjaro and Zepbound.

But if you have $1,000 to put into the market, there are several quality names that offer significant upside even though—in some cases—they've outperformed the market in 2025. In other words, if you're looking for long-term growth, there are opportunities available that will allow you to generate a solid return without the volatility that can come with low-priced stocks.

Novo Nordisk (NVO 2.60%), a Denmark-based drugmaker, was a pioneer in the GLP-1 market. The pharmaceutical giant launched medicines like Ozempic and Wegovy, which became hugely famous and successful brand names.

Eli Lilly and Co (NYSE:LLY) will report its third quarter 2025 earnings next Thursday, with Bank of America analysts closely watching how the company's obesity and diabetes treatments are performing amid ongoing policy debates over US drug pricing. The firm believes the drugmaker's upcoming report could offer insight into the company's key brands while highlighting broader industry trends affec...

Obesity, type 2 diabetes, and cancer continue to grow across the globe, but pharma stocks remain off the radars of many investors. Many of them consistently beat the Street's consensus estimates and offer dividend yields even higher than IT, as well as oil and gas stocks. In this article, I reveal my top 3 Big Pharma players.